Drug Information

Drug (ID: DG02153) and It's Reported Resistant Information

• Name: JNK1 inhibitors
• Synonyms: JNK1 inhibitors
• Indication:
  In total 1 Indication(s)
  . .; .; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Chronic lymphocytic leukemia [ICD-11: 2A82]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) [1]

• Sensitive Disease: Chronic lymphocytic leukemia [ICD-11: 2A82.0]
• Molecule Alteration: Phosphorylation; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: B cell receptor signaling pathway; Inhibition; hsa04662
• In Vitro Model: 3T3-msCD40L cells; Embryo; Homo sapiens (Human); CVCL_1H10
• In Vitro Model: M2-10B4 cells; Bone marrow; Homo sapiens (Human); CVCL_5794
• In Vivo Model: NOG mice; Eu-TCL1-tg mice; Mus musculus
• Experiment for Molecule Alteration: Immunoblotting assay
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: JNK1 inhibition affects BCL2 and MCL1 expression in CLL;JNK1 inhibition reduces CLL cell viability preferentially in IGHV unmutated CLLs and overcomes stromal protective effects;JNK1 is a crucial downstream mediator of BCR signaling in CLL.

Key Molecule: Mitogen-activated protein kinase 8 (MAPK8) [1]

• Sensitive Disease: Chronic lymphocytic leukemia [ICD-11: 2A82.0]
• Molecule Alteration: Phosphorylation; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: B cell receptor signaling pathway; Inhibition; hsa04662
• In Vitro Model: 3T3-msCD40L cells; Embryo; Homo sapiens (Human); CVCL_1H10
• In Vitro Model: M2-10B4 cells; Bone marrow; Homo sapiens (Human); CVCL_5794
• In Vivo Model: NOG mice; Eu-TCL1-tg mice; Mus musculus
• Experiment for Molecule Alteration: Immunoblotting assay
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: JNK1 inhibition affects BCL2 and MCL1 expression in CLL;JNK1 inhibition reduces CLL cell viability preferentially in IGHV unmutated CLLs and overcomes stromal protective effects;JNK1 is a crucial downstream mediator of BCR signaling in CLL.

Key Molecule: B-cell lymphoma 2 (BCL2) [1]

• Sensitive Disease: Chronic lymphocytic leukemia [ICD-11: 2A82.0]
• Molecule Alteration: Phosphorylation; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: B cell receptor signaling pathway; Inhibition; hsa04662
• In Vitro Model: 3T3-msCD40L cells; Embryo; Homo sapiens (Human); CVCL_1H10
• In Vitro Model: M2-10B4 cells; Bone marrow; Homo sapiens (Human); CVCL_5794
• In Vivo Model: NOG mice; Eu-TCL1-tg mice; Mus musculus
• Experiment for Molecule Alteration: Immunoblotting assay
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: JNK1 inhibition affects BCL2 and MCL1 expression in CLL;JNK1 inhibition reduces CLL cell viability preferentially in IGHV unmutated CLLs and overcomes stromal protective effects;JNK1 is a crucial downstream mediator of BCR signaling in CLL.

Key Molecule: Oncogenic transcription factor c-Jun [1]

• Sensitive Disease: Chronic lymphocytic leukemia [ICD-11: 2A82.0]
• Molecule Alteration: Phosphorylation; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: B cell receptor signaling pathway; Inhibition; hsa04662
• In Vitro Model: 3T3-msCD40L cells; Embryo; Homo sapiens (Human); CVCL_1H10
• In Vitro Model: M2-10B4 cells; Bone marrow; Homo sapiens (Human); CVCL_5794
• In Vivo Model: NOG mice; Eu-TCL1-tg mice; Mus musculus
• Experiment for Molecule Alteration: Immunoblotting assay
• Experiment for Drug Resistance: Flow cytometry assay
• Mechanism Description: JNK1 inhibition affects BCL2 and MCL1 expression in CLL;JNK1 inhibition reduces CLL cell viability preferentially in IGHV unmutated CLLs and overcomes stromal protective effects;JNK1 is a crucial downstream mediator of BCR signaling in CLL.

References

• Ref 1: JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL. J Exp Med. 2025 Jan 6;222(1):e20230681.